Hao Feng Medical Completes Nearly RMB 100 Million Pre-B Financing Round, Aiming to Become a Global Leader in Interventional Medical Device CDMO

VCBeat learned第一时间 that recently,Shanghai Hao Feng Medical Technology Co., Ltd. (hereinafter referred to as“Haofeng Medical”) Announced CompletionNearly 100 millionYuanRMBPre-BRound of Financing, this round of financing was led byZhuhai High tech Financial Investment Co., LtdLed by, existing shareholdersCenova CapitalContinuous investment. This follows the previous round of exclusive investment by Cenova Capital, with the company gaining favor in the capital market again in less than a year.Xizhiqiao CapitalServed as the exclusive financial advisor for the company in this round of financing.

The funds raised in this round will be used for the company's continuous capacity expansion, business development, and global layout, in order to better meet the diversified service needs of different types of customers.

In developed countries in Europe and America, the CDMO business model in the medical device field has gradually matured, with industrial division deeply rooted. In recent years, high-value medical consumables have rapidly developed in China, and the trend of refined supply chain division has become increasingly evident. CDMO services for high-value consumables, including interventional products, are entering a period of rapid growth. Haofeng Medical accurately judged the industry trend, leveraging its leading market position in the equipment sector, years of refining its supply chain system, and long-term cooperation with hundreds of domestic and international downstream customers.Rapidly built a comprehensive service platform for the three core businesses of component CDMO, intelligent equipment, and materials, providing customers with high-quality one-stop services.

A Highly Recognized Component CDMO Platform in the Industry:The company has accumulated years of experience in the interventional consumables industry, adhering to the customer service principle of never obtaining registration certificates on behalf of clients. With a deep understanding of the pain points and needs of downstream customers, it has built a CDMO platform for three key components—balloon catheters, interventional catheters, and interventional guidewires—spanning across various fields such as泛血管介入 (pan-vascular intervention),泌尿介入 (urological intervention),消化介入 (gastrointestinal intervention), and肿瘤介入 (oncological intervention). Additionally, the company has established technical development platforms for specialized material welding technology, material forming technology, precision assembly processing technology, and surface functional hybridization technology.

The supply chain management team of the company combines the lean production background of Japanese enterprises with the high-standard production requirements of the medical device industry. With rich production management experience, the company has built a first-class lean production culture for high-value consumables in China, implemented comprehensive quality management, strictly controlled delivery standards, and improved production efficiency to continuously create market value for customers. The balloon catheter products such as coronary balloons, peripheral balloons, and active consumables like steerable sheaths produced by the company have gained high recognition from customers.

Advanced intelligent equipment platform with leading production technology:The company is the leading supplier in China that provides production and testing equipment for all categories of interventional consumables, covering product lines such as balloon catheters, interventional catheters, and interventional guidewires, and its products are exported overseas. In the single product category of hydrophilic coating equipment, the company has formed a strategic partnership with the international giant Royal DSM of the Netherlands. Haofeng Medical's hydrophilic coating equipment and supporting testing equipment have received the only certification in the Asia-Pacific region from Royal DSM.

Material Platform for Breakthrough "Bottleneck" Technologies:The company has an outstanding team of material developers in the industry. After years of research and exploration, the company's materials and tubing can rival imported products in terms of modification and extrusion processes. In performance comparisons, the parameters of the company’s PTFE, PET, and FEP tubing fully match those of imported products.

Haofeng Medical Group and its subsidiary CDMO business have respectively obtained the National High-tech Enterprise Certification and municipal "Specialized, Refined, Unique, and Innovative" enterprise certification. The company has also acquired over 130 national authorized patents and software copyrights. All products in the company’s portfolio are fully independently intellectual property-owned, with some products having received CE certification. Additionally, the company has passed ISO9001 and ISO13485 quality management system certifications, as well as GB/T 29490 intellectual property compliance management system certification.

Currently, the company's comprehensive service platform can provide customers with one-stop services, including full lifecycle management and manufacturing services from product research and development design, pre-registration production to post-market contract manufacturing, as well as customized intelligent production lines for customers.

In terms of international expansion, the company has reached strategic partnerships with leading clients in Europe, Latin America, and Southeast Asia, taking a significant step towards becoming a global medical device CDMO platform.

Chairman of Haofeng Medical, Liu ChunjieSaid: "In recent years, the high-value medical consumables market in China has been booming, driven by strong demand, the pursuit of high-quality products, and the localization of supply chains, which have fueled the rapid development of the domestic medical device industry. The medical device industry needs capacity, but more importantly, it needs high-quality capacity. How to develop new productivity for the industry and continuously empower customers through innovation is the top priority of our CDMO industry’s work. Haofeng Medical, with years of deep cultivation in the high-value medical consumables sector, has built an intelligent equipment, component CDMO, and materials comprehensive service platform. We deeply understand the urgency and importance of platform-based services in meeting the diverse needs of downstream customers. The company is committed to becoming a lean production expert in the medical device field, creating a high-quality, efficient, and comprehensive medical device service supply chain for customers. We sincerely thank both new and existing shareholders for their recognition of Haofeng Medical. The company will forge ahead, stay true to its original mission, strive to build the number one CDMO brand in the medical device industry, and become the most trusted strategic partner for global medical device enterprises."

Zhuhai High tech Financial Investment Co., Ltd"It is reported that the interventional medical device is one of the fastest-growing medical device sectors in China. Zhuhai High tech Financial Investment Co., Ltd. has been closely monitoring the development of China's high-end medical device sector and has maintained a strong interest in investment opportunities within the emerging sub-sector of domestic interventional medical devices in recent years. Haofeng Medical, as a company committed to building a one-stop service platform for downstream interventional medical device clients, provides the industry’s highest-quality industrial chain services. With a well-established commercial layout in the interventional medical device field and deep client relationships, we look forward to Haofeng Medical becoming the most trusted medical device industrial chain service provider in the industry, continuously contributing to the growth and expansion of China's interventional medical device sector."

Cenova CapitalCenova Capital stated: "Cenova has long been focused on opportunities across the entire medical device industry chain. After more than a decade of development, the innovation capabilities of domestic device companies have grown stronger. The demand for efficiency in production and R&D has also increased, and industrial division has become more defined. The upstream segment of the medical device industry is approaching an inflection point for growth. Haofeng Medical, leveraging years of expertise in interventional product equipment and processes, combined with the team's advantage in lean management, has established a one-stop interventional device CDMO. We hope to continuously support the company’s development and provide higher quality and more efficient services to customers in China and globally."

Lu Rongchao, Partner of Xizhiqiao Capital"Congratulations to Haofeng Medical for successfully completing two rounds of financing within the year. I have personally witnessed the company's rapid development and innovative transformation over the past three years. The medical device CDMO sector is a track that truly tests a company’s patience, resilience, and comprehensive operational capabilities. Under the leadership of Founder Liu, I believe the team will continue to provide high-value-added services to downstream clients and become a globally leading brand in the medical device CDMO field."

Zhuhai High tech Financial Investment Co., Ltd. is the wholly state-owned investment management platform of Zhuhai High-tech Zone. As the government investment fund manager and a value investor adhering to long-termism, Zhuhai High tech Financial Investment Co., Ltd. consistently focuses on the "3+3+1" strategy, emphasizing the investment philosophy of "investing early, investing small, and investing in technology." With a specialty in seed-stage and start-up venture capital funds, it has formed a full-chain investment system covering the entire life cycle of enterprises from growth and expansion stages to maturity. Throughout the entire development process of enterprises, it provides support in financial resources, technological resources, and other aspects, continuously increasing its support for early-stage enterprises to help them grow rapidly.

Cenova Capital was founded in 2010 by Dr. Wu Jun and is one of the earliest professional funds in China dedicated to investment in the healthcare and life sciences sectors, committed to promoting the transformation, upgrading, and innovation of China's healthcare industry. Cenova Capital currently manages five healthcare industry funds and has invested in more than 50 enterprises in the healthcare and life sciences fields. The fund’s contributors are internationally and domestically renowned institutional investors, including Asian sovereign wealth funds, government agencies, domestic and international insurance and financial institutions, and multinational corporations.

Xizhiqiao Capital is a boutique investment bank specializing in the healthcare and hard technology sectors. The team members have years of experience in investment banking, investment, and industry fields, possessing abundant resources within the industry’s ecosystem. The company was founded with the original intention of building a bridge between enterprises and the capital market with professionalism and dedication, providing diversified financial and strategic consulting services, including but not limited to equity financing, mergers and acquisitions, and cross-border transactions.